Workflow
礼来:记能达对早期症状性阿尔茨海默病显示出三年持续增强获益

Core Insights - Eli Lilly announced long-term extension results from its TRAILBLAZER-ALZ2 Phase 3 clinical study, showing significant disease progression slowdown in participants treated with donanemab compared to an untreated cohort from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database [1] - The benefits of donanemab treatment continued to enhance over a three-year period, indicating sustained efficacy [1] - Participants who started treatment later still experienced benefits, but those who received early treatment had a significantly lower risk of progressing to the next stage of the disease compared to the delayed treatment group [1] - These findings were presented at the 2025 Alzheimer's Association International Conference (AAIC) held in Toronto [1]